Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
billionaires . Eli Lilly and Company (NYSE:LLY) announced on March 16 positive topline results from the Phase 3 ADorable-1 trial that was evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis. Management stated that EBGLYSS met the primary and key secondary endpoints at Week 16, improving disease severity while delivering skin clearance and relief from persistent itch. Eli Lilly and Company (NYSE:LLY) has plans to submit the data to U.S. and global regulators for a potential label update. RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results In a separate development, Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in a research note that it believes expectations for the total addressable market for obesity are elevated at over $150 billion, a
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]Yahoo! Finance
- Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern [Yahoo! Finance]Yahoo! Finance
- RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results [Yahoo! Finance]Yahoo! Finance
- Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? [Yahoo! Finance]Yahoo! Finance
- Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- 3/17/26 - Form 4
- LLY's page on the SEC website